benzyl N-[(3-nitrophenyl)methyl]carbamate | 959906-87-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl N-[(3-nitrophenyl)methyl]carbamate
• CAS: 959906-87-7
• 化学式: C₁₅H₁₄N₂O₄
• 分子量: 286.287
• InChiKey: XUUQYHBCKSPUAI-UHFFFAOYSA-N

物化性质

• 熔点：
  67-68 °C
• 沸点：
  495.0±38.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl N-[(3-nitrophenyl)methyl]carbamate 在 镍 氢气 作用下， 以 甲醇 为溶剂， 生成 3-N-cbz-氨基甲基苯胺
  参考文献：
  名称：

  Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain

  摘要：

  We have designed and synthesized a (3-aminomethyl-phenyl)-urea scaffold to mimic the X+1-Asn part of the minimal phosphopeptide sequence, Ac-pTyr-X+1-Asn-NH2, recognized by the Grb2-SH2 domain. The resulting compounds show the same degree of affinity as their peptide counterparts for the Grb2-SH2 domain. This is the first example reported to date of ligands of the Grb2-SH2 domain with substantially reduced peptidic character. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00513-7
• 作为产物：
  描述：

  3-硝基苄胺盐酸盐 、 氯甲酸苄酯 在 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 以10%的产率得到benzyl N-[(3-nitrophenyl)methyl]carbamate
  参考文献：
  名称：

  Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain

  摘要：

  We have designed and synthesized a (3-aminomethyl-phenyl)-urea scaffold to mimic the X+1-Asn part of the minimal phosphopeptide sequence, Ac-pTyr-X+1-Asn-NH2, recognized by the Grb2-SH2 domain. The resulting compounds show the same degree of affinity as their peptide counterparts for the Grb2-SH2 domain. This is the first example reported to date of ligands of the Grb2-SH2 domain with substantially reduced peptidic character. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00513-7

文献信息

• Iron-Catalyzed Four-Component Reaction for the Synthesis of Protected Primary Amines
  作者：Bai-Ling Yang、Shi-Kai Tian

  DOI：10.1002/ejoc.200700627

  日期：2007.10

  developed to produce protected primary amines by a novel tandem nitrogen protection/direct reductive amination of carbonyl compounds. In the presence of 5 mol-% of an iron(II) salt, a wide variety of aldehydes and ketones were transformed into their corresponding protected primary amines in good to excellent yields under “pure” multicomponent reaction (MCR) conditions. This chemistry was further extended

  羰基化合物与氯甲酸烷基酯、HMDS 和 Et3SiH 的第一个催化四组分反应 (4CR) 已开发用于通过羰基化合物的新型串联氮保护/直接还原胺化来生产受保护的伯胺。在 5 mol-% 的铁 (II) 盐的存在下，在“纯”多组分反应 (MCR) 条件下，各种醛和酮以良好至极好的收率转化为相应的受保护伯胺。这种化学反应进一步扩展到掩蔽的羰基化合物，如缩醛、缩酮和乙烯基醚。与之前从大量过量的氨或铵盐中制备受保护伯胺的方法相比，这种 4CR 不仅节省了至少一个合成操作步骤，但也利用了接近化学计量的氮和氢源，避免了（受保护的）仲胺的形成。该协议的其他优点包括更广泛的底物范围、使用廉价且环保的催化剂以及温和的反应条件。 (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)
• MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1971582B1

  公开（公告）日：2012-10-10
• [EN] MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS<br/>[FR] INHIBITEURS DU FACTEUR MACROCYCLIQUE VIIA UTILES EN TANT QU'ANTICOAGULANTS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2007076431A1

  公开（公告）日：2007-07-05

  [EN] The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, thereof, wherein the variables A, B, L, M, W, Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.
  [FR] La présente invention concerne de manière générale de nouveaux macrocycles de formule (I) : ou des stéréoisomères, des tautomères, des sels pharmaceutiquement acceptables, des solvates de ces composés, les variables A, B, L, M, W, Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ et R¹⁰ étant définies dans le présent document. Ces composés constituent des inhibiteurs sélectifs du facteur de coagulation de sérine protéase VIIa pouvant être utilisés en tant que médicaments.
• Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain
  作者：Joseph Schoepfer、Brigitte Gay、Giorgio Caravatti、Carlos Garcia-Echeverria、Heinz Fretz、Joseph Rahuel、Pascal Furet

  DOI：10.1016/s0960-894x(98)00513-7

  日期：1998.10

  We have designed and synthesized a (3-aminomethyl-phenyl)-urea scaffold to mimic the X+1-Asn part of the minimal phosphopeptide sequence, Ac-pTyr-X+1-Asn-NH2, recognized by the Grb2-SH2 domain. The resulting compounds show the same degree of affinity as their peptide counterparts for the Grb2-SH2 domain. This is the first example reported to date of ligands of the Grb2-SH2 domain with substantially reduced peptidic character. (C) 1998 Elsevier Science Ltd. All rights reserved.